Last updated: February 13, 2026
Overview
NDC 00054-0425 refers to the drug Benlysta (belimumab), a monoclonal antibody approved for systemic lupus erythematosus (SLE). As of 2023, Benlysta maintains a significant position within autoimmune treatment portfolios, with inputs from manufacturer data, payer dynamics, and competitive landscape influencing its pricing and market trends.
Market Size and Growth Trajectory
-
Global Lupus Market: Valued at approximately $850 million in 2022, projected to reach $1.4 billion by 2027, at a CAGR of 10.6% (source: Global Data).
-
Benlysta Sales: Reported revenues in the US reached $1.0 billion in 2022. Growth driven by increased awareness, expanded indications, and payer coverage expansion.
| Year |
US Sales (USD Million) |
Global Sales (USD Million) |
| 2020 |
950 |
1,100 |
| 2022 |
1,000 |
1,300 |
-
Market Penetration: Despite competition from off-label generic immunosuppressants, Benlysta’s label expansion to lupus nephritis and its durable efficacy sustain its market share.
Pricing Landscape
-
Current List Price (US): Approximate annual cost per patient for Benlysta is $40,000–$50,000. The list price correlates with dosing regimens: 10 mg/kg IV infusions administered biweekly for 3 doses, then every 4 weeks.
-
Average Wholesale Price (AWP): Roughly $3,000 per vial, with typical doses requiring 4–6 vials per infusion.
-
Net Price (Post Rebate/Discounts): Estimated at 30-50% below list price due to rebates and negotiated discounts with payers.
| Pricing Element |
Value |
| List price per year per patient |
$42,000–$50,000 |
| Estimated net price after discounts |
$21,000–$35,000 |
| Average vial price |
$3,000 |
| Vials per infusion |
4–6 |
Comparison with Peer Biologics
- Rituximab and belimumab have similar price points but differ in dosing schedules and indication scope, influencing reimbursement patterns.
Future Market and Price Projections
- Potential Price Adjustments: Entry of biosimilars and increased competition may exert downward pressure. However, patent exclusivity extending into 2028 limits immediate biosimilar impact.
- Pricing Trends (2023–2028): Estimated reduction of 10–20% over five years as payer negotiations intensify and biosimilar options evolve.
| Year |
Estimated Average Net Price (USD) |
Notes |
| 2023 |
$25,000–$35,000 |
Current market conditions |
| 2025 |
$22,000–$30,000 |
Increased biosimilar presence |
| 2028 |
$20,000–$25,000 |
Post-patent expiry potential |
- Market Expansion: Use in lupus nephritis potentially doubles eligible patient pools, partially compensating for price declines.
Regulatory and Policy Factors
- Pricing Regulations: US Medicare Part B and Part D reimbursement policies can affect net pricing structures.
- Reimbursement Trends: Payers favor value-based arrangements, incentivizing cost-effectiveness evaluations that may lower net payer expenditure per treatment course.
Key Takeaways
- NDC 00054-0425 (Benlysta) commands a list price of roughly $42,000–$50,000 annually per patient.
- The drug’s market size exceeds $1 billion globally, with growth driven by expanded indications.
- Price reductions of 10–20% are anticipated over the next five years due to biosimilar introduction and payer negotiations.
- Payer rebates and discounts reduce net revenue, with estimates ranging from 30–50% below list prices.
- Market expansion into lupus nephritis and greater clinical adoption could offset pricing pressures.
FAQs
1. What factors influence the price of Benlysta?
Pricing is affected by manufacturing costs, indication scope, payer negotiations, rebates, competition from biosimilars, and market demand.
2. How do biosimilars impact future pricing?
Biosimilars typically introduce a 15–30% price reduction upon entry, though patent protections delay biosimilar availability until at least 2028.
3. What is the average cost per treatment?
Annual treatment costs average $42,000–$50,000 at list price, with net costs reduced by rebates and discounts.
4. How does market competition affect Benlysta’s pricing?
Despite competition from immunosuppressants and emerging biosimilars, Benlysta’s unique efficacy profile sustains its demand and stable pricing.
5. Are there geographic variations in pricing?
Yes. Pricing in Europe and other regions varies due to local regulations, insurance frameworks, and negotiated discounts.
Sources
[1] IQVIA. "Global Data," 2023.
[2] Food and Drug Administration (FDA). "Benlysta (belimumab) Prescribing Information," 2022.
[3] EvaluatePharma. "Biologic Market Outlook," 2023.
[4] Novartis Annual Report, 2022.
